An anonymous reader quotes a report from MIT Technology Review: The pig heart transplanted into an American patient earlier this year in a landmark operation carried a porcine virus that may have derailed the experiment and contributed to his death two months later, say transplant specialists. [...] In a statement released by the university in March, a spokesperson said there was "no obvious cause identified at the time of his death" and that a full report was pending. Now MIT Technology Review has learned that Bennett's heart was affected by porcine cytomegalovirus, a preventable infection that is linked to devastating effects on transplants.

The presence of the pig virus and the desperate efforts to defeat it were described by Griffith during a webinar streamed online by the American Society of Transplantation on April 20. The issue is now a subject of wide discussion among specialists, who think the infection was a potential contributor to Bennett's death and a possible reason why the heart did not last longer. The heart swap in Maryland was a major test of xenotransplantation, the process of moving tissues between species. But because the special pigs raised to provide organs are supposed to be virus-free, it now appears that the experiment was compromised by an unforced error. The biotechnology company that raised and engineered the pigs, Revivicor, declined to comment and has made no public statement about the virus. "It was surprising. That pig is supposed to be clean of all pig pathogens, and this is a significant one," says Mike Curtis, CEO of eGenesis, a competing company that is also breeding pigs for transplant organs. "Without the virus, would Mr. Bennett have lived? We don't know, but the infection didn't help. It likely contributed to the failure."

NBC News is reporting that the United States has officially surpassed 1 million COVID-19 deaths -- "a once unthinkable scale of loss even for the country with the world's highest recorded toll from the virus." From the report: The number -- equivalent to the population of San Jose, California, the 10th largest city in the U.S. -- was reached at stunning speed: 27 months after the country confirmed its first case of the virus. While deaths from Covid have slowed in recent weeks, about 360 people have still been dying every day. The casualty count is far higher than what most people could have imagined in the early days of the pandemic [...].

Now, more than two years and 999,999 fatalities later, the U.S. death toll is the world's highest total by a significant margin, figures show. In a distant second is Brazil, which has recorded just over 660,000 confirmed Covid deaths.

Researchers at the Terasaki Institute have now shown that silk scaffolds loaded with stem cells can help tendons regenerate more effectively. New Atlas reports: For the new study, the Terasaki researchers developed their own scaffold that could support the tendon while it healed. This scaffold was made of silk fibroin paired with a hydrogel known as GelMA -- the former gave the scaffold strength and stretchability, while the latter is biocompatible and encourages cells to attach and grow. After experimenting to get the right ratios of ingredients, the team fabricated nanofiber sheets of their silk fibroin and GelMA (SG) material. Then the sheets are seeded with mesenchymal stem cells (MSCs), which can not only differentiate into several cell types, but also aid regeneration by producing signaling molecules that summon immune cells to the area and encourage new blood vessels to form.

The team tested these stem-cell-loaded SG sheets in rats with injuries to their Achilles tendons. Compared to other scaffolds loaded with stem cells, those made of SG healed the tendons the fastest, while also forming densely packed tendon fibers, reducing injury sites, and remodeling the muscle components. "The synergistic effects of GelMA's capacity for supporting regenerative tissue formation and the structural advantages of silk fibroin make our composite material well suited for tendon repair," said HanJun Kim, lead researcher on the study. The team hopes that with further work, the stem-cell-loaded scaffolds could eventually lead to new therapies for tendon injuries. The research has been published in the journal Small.

Efforts to tease apart the vast swarm of proteins in venom -- a field called venomics -- have burgeoned in recent years, leading to important drug discoveries. From a report: In a small room in a building at the Arizona-Sonora Desert Museum, the invertebrate keeper, Emma Califf, lifts up a rock in a plastic box. "This is one of our desert hairies," she said, exposing a three-inch-long scorpion, its tail arced over its back. "The largest scorpion in North America." This captive hairy, along with a swarm of inch-long bark scorpions in another box, and two dozen rattlesnakes of varying species and sub- species across the hall, are kept here for the coin of the realm: their venom. Efforts to tease apart the vast swarm of proteins in venom -- a field called venomics -- have burgeoned in recent years, and the growing catalog of compounds has led to a number of drug discoveries. As the components of these natural toxins continue to be assayed by evolving technologies, the number of promising molecules is also growing.

"A century ago we thought venom had three or four components, and now we know just one type of venom can have thousands," said Leslie V. Boyer, a professor emeritus of pathology at the University of Arizona. "Things are accelerating because a small number of very good laboratories have been pumping out information that everyone else can now use to make discoveries." She added, "There's a pharmacopoeia out there waiting to be explored." It is a striking case of modern-day scientific alchemy: The most highly evolved of natural poisons on the planet are creating a number of effective medicines with the potential for many more.

One of the most promising venom-derived drugs to date comes from the deadly Fraser Island funnel web spider of Australia, which halts cell death after a heart attack. Blood flow to the heart is reduced after a heart attack, which makes the cell environment more acidic and leads to cell death. The drug, a protein called Hi1A, is scheduled for clinical trials next year. In the lab, it was tested on the cells of beating human hearts. It was found to block their ability to sense acid, "so the death message is blocked, cell death is reduced, and we see improved heart cell survival," said Nathan Palpant, a researcher at the University of Queensland in Australia who helped make the discovery.

An anonymous reader quotes a report from NPR: Is polio making a comeback? The world has spent billions of dollars over the last 15 years in an effort to wipe out the virus through vaccination efforts -- with encouraging results. Rates plunged from an estimated 350,000 cases in 1988 to just several dozen by 2016. But in recent years, polio incidence has started to inch back up. The reason has to do with the type of vaccine used in many parts of the world, primarily in low- and middle-income countries. While the United States and other Western countries inject an inactivated virus that poses no risk of spread and are now polio-free, other countries rely on an oral vaccine. It's cheap, it's easy to administer and two or more doses confer lifelong immunity. But it's made with living, weakened virus. And that poses a problem.

Those who've been immunized with live virus can shed it in their stool, which can then spread through sewage in places with poor sanitation. If the virus stays weak, it can even expose the unvaccinated to polio and give them immunity. But if it mutates and regains virulence, someone who isn't vaccinated can become sick with vaccine-derived polio after contact with the contaminated wastewater. And now countries that had previously eradicated polio in Africa, the Middle East and parts of Asia are seeing new outbreaks of vaccine-derived polio.

One reason for this rise in cases, say polio experts, is that gaps in immunization in recent years have created more opportunities for the unvaccinated to become infected. "Vaccination campaigns have been certainly affected by the pandemic," says Raul Andino, a virologist at University of California, San Francisco. [...] The composition of the oral vaccine has also been a factor. In 2016, eyeing an uptick in vaccine-derived polio, global health officials altered the composition of the oral vaccine. Previously, the vaccine protected against all three types of wild polio -- the virus that circulates naturally in the environment. Then they withdrew one of those types -- the one that was leading to most of the vaccine-derived cases but whose wild form had been successfully eradicated. Only there was a development that hadn't been anticipated. Vaccine-derived poliovirus of that type was still in circulation from earlier iterations of the oral vaccine -- and now with the reformulated vaccine, increasing numbers of people who were no longer vaccinated against it. So there was further spread. Thankfully, a new kind of vaccine being rolled out is showing promise. "The novel vaccine still contains a weakened version of the virus, but it's been hobbled even further," reports NPR.

"The researchers tweaked the virus so that it has to accumulate more mutations to become virulent and has a harder time amassing those mutations. For example, they've altered the polymerase, one of the key enzymes responsible for introducing mutations, reducing its ability to mix and match genes from different viruses."

The common perception that nearly everyone in America seemed to have acquired the Omicron variant last winter may not have been far from the truth. By February 2022, nearly 60 percent of the population had been infected with the coronavirus, almost double the proportion seen in December 2021, according to data released on Tuesday by the Centers for Disease Control and Prevention. The New York Times reports: "By February 2022, evidence of previous Covid-19 infections substantially increased among every age group," Dr. Kristie Clarke, the agency researcher who led the study, said at a news briefing. Infections rose most sharply during the Omicron surge among children and adolescents, perhaps because many people in those age groups were still unvaccinated. The increase was smallest among adults 65 or older, who have the highest rate of vaccination and may be the most likely to take precautions. The new research suggests that three out of four children and adolescents in the United States had been infected with the coronavirus by February 2022, compared with one-third of older adults.

While some studies suggest that prior infection offers a weaker shield against the virus than vaccines do, the resulting antibodies should provide a reasonable degree of protection against severe illness, at least in the short term. "We still do not know how long infection-induced immunity will last," Dr. Clarke said. The gains in population-wide immunity may explain why the new surge that is roaring through China and many countries in Europe has been muted in the United States so far. The findings may offer some comfort to parents who have been waiting anxiously for a vaccine to be approved for the youngest children. Many of those children now seem to have acquired at least some immunity. Even so, Dr. Clarke urged parents to immunize children who qualify as soon as regulators approve a vaccine for them, regardless of any prior infection.

A group of TikTok- and Instagram-famous physicians say they have a solution for the "red tape" of the current medical system: NFTs of cartoon doctors. From a report: These NFTs, called MetaDocs, are supposed to give buyers access to real doctors, almost like a Web3 telehealth subscription. When MetaDocs launched in December, it claimed that its legion of celebrity doctors, who have a collective social media following of 70 million and have included "Dr. Pimple Popper" Sandra Lee and plastic surgeon Dr. Richard Brown of TikTok fame, would all be available via DM, group "ask me anything" sessions, or one-on-one video chats to those who buy in. MetaDocs founder Dr. Sina Joorabchi hopes it will evolve into a full-fledged virtual clinic in the so-called metaverse, where patients can put on a haptic suit and be examined remotely by a physician in virtual reality.

But now, MetaDocs is facing backlash from the medical community, in part because it is not actually licensed as a telemedicine service and thus its doctors cannot legally make diagnoses, write prescriptions, or give personalized medical advice to anyone who buys a MetaDocs NFT. A further wrinkle: Doctors are almost always required to be licensed in a state in order to practice there, including through telehealth services. "At this point, we're hesitant to refer to anybody as a patient," Dr. Dustin Portela, a MetaDocs physician and practicing dermatologist, told BuzzFeed News. According to a recent white paper, the presale cost of a MetaDocs NFT will be 0.2 ETH, or about $570, though the company hasn't determined an exact price yet. But why would someone pay hundreds of dollars for a cartoon so they could "ask a doctor anything" if they are not seeking some form of medical advice?

Bill Gates shares a statistic about the COVID-19 pandemic. "If we'd been able to stop it within 100 days, we would've saved over 98% of the lives." "Viruses spread exponentially, and so if you get in there when the infection rate is fairly small, you can actually stop the spread."
In a new TED talk, Gates argues that we did learn a lot from this pandemic — enough to build a prevention system for next time. "Covid 19 can be the last pandemic if we take the right steps." But the answer isn't vaccines. "We also need vaccines, but we want to stop the outbreak before we have to do a global vaccination campaign." And then Gates points out that currently it could take months to get resources to a low-income country experiencing an outbreak.

Read on for Slashdot's report on Gates' proposed solution — and how he feels about his own prominence in anti-vaccine misinformation.

Once every 10 years there's a report released by America's National Academies of Sciences, Engineering, and Medicine.

Released this year, the report recommends prioritizing a mission to the planet Uranus to map its gravitational and magnetic fields and study how the planet's internal heat moves to the surface.

BGR reports: Despite being the seventh planet in our solar system, there's very little we know about Uranus as a whole. In fact, one of the best images we have of the planet was captured in 1986 by the Voyager 2... Additionally, scientists want to learn more about the various moons that surround the planet. We also know very little about the ring system that surrounds the blue planet. A team led by Mark Hofstadter, a planetary scientist with NASA's Jet Propulsion Lab wrote a white paper on their goals....

We currently already have the tech we need to get a spacecraft there that can orbit the planet. Additionally, scientists have found that launching a mission in 2031 would allow us to capitalize on gravity assistance from Jupiter.
The report also recommends studying Enceladus, an icy moon orbiting Saturn which has shown signs it could sustain microbial life.

Thanks to Slashdot reader alaskana98 for submitting the story.

Analysis of thousands of tumours has unveiled a treasure trove of clues about the causes of cancer, representing a significant step towards the personalisation of treatment. The Guardian: Researchers say that for the first time it is possible to detect patterns -- called mutational signatures -- in the DNA of cancers. These provide clues including about whether a patient has had past exposure to environmental causes of cancer such as smoking or UV light, for example. This is important as these signatures allow doctors to look at each patient's tumour and match it to specific treatments and medications. However, these patterns can be detected only through analysis of the vast amounts of data unearthed by whole genome sequencing -- identifying the genetic makeup of a cell.

China's largest city has recorded just 17 Covid deaths, despite surging cases. How China defines a Covid death may be part of the reason. The New York Times: By the numbers, Shanghai has been an exemplar of how to save lives during a pandemic. Despite the city's more than 400,000 Covid-19 infections, just 17 people have died, according to officials, statistics they have touted as proof that their strategy of strict lockdowns and mass quarantines works. But those numbers may not give a complete picture of the outbreak's toll. China typically classifies Covid-related deaths more narrowly than many other countries, labeling some chronically ill patients who die while infected as victims of those other conditions. In addition, a nearly three-week lockdown of China's biggest city has limited access to medicine and care for other illnesses. A nurse who suffered an asthma attack died after being denied care because of virus controls. A 90-year-old man died of complications from diabetes after being turned away from an overwhelmed hospital.

"If, at the time, he had been able to get treatment, he probably would have survived," said the man's granddaughter, Tracy Tang, a 32-year-old marketing manager. Residents and frontline workers have also been pushed to their limits by the policies. A hospital worker started bleeding internally after long hours conducting mass testing; she, too, died. It may never become clear how many similar stories there are. China does not release information on excess deaths, defined as the number of deaths -- from Covid as well as other causes -- exceeding the expected total in a given period. Public health scholars say that figure more accurately captures losses during the pandemic, as countries define Covid-related deaths differently. But as an example of the hidden impacts, a prominent Chinese physician recently estimated that nearly 1,000 more diabetes patients could die than expected during Shanghai's lockdown, urging the authorities to take a more measured response.

The outbreak there has revived questions about the true toll of Covid in China, which has officially reported fewer than 5,000 deaths from the coronavirus in two years. Beijing is unlikely to waver from its stringent approach. China's leader, Xi Jinping, has made the country's low death and infection rates central to his administration's legitimacy. Officials have been fired after even a few cases were detected in their jurisdictions. Last week, Mr. Xi said that "prevention and control work cannot be relaxed." The focus on minimizing Covid deaths risks incentivizing officials to neglect other causes of death, said Xi Chen, a professor of public health at Yale.

The Covid-19 pandemic "would look very different if scientists had been able to develop a treatment sooner," writes Bill Gates, in a guest essay Friday in the New York Times. This ultimately would've reduced fatalities — "and it may have been harder for myths and misinformation to spread the way they did."

But note that Gates said "treatment" — not vaccine. Gates believes most people in the public health community had expected an effective treatment would appear before vaccines became available. Unfortunately, that's not what happened. Safe, effective Covid vaccines were available within a year — a historic feat — but treatments that could keep large numbers of people out of the hospital were surprisingly slow out of the gate....

In late 2021, a few of their efforts paid off — not as soon as would have been ideal, but still in time to have a big impact. Merck and its partners developed an antiviral called molnupiravir, which was shown to significantly reduce the risk of hospitalization or death for people at high risk. Soon after, another oral antiviral, Paxlovid, made by Pfizer, also proved to be very effective, reducing the risk of severe illness or death by nearly 90 percent among high-risk, unvaccinated adults. These drugs are useful tools for combating the pandemic, but they arrived much later than they should have and, for many, they are still difficult to access....

It's a mistake to think of vaccines as the star of the show and therapeutics as the opening act you would just as soon skip. We're lucky that scientists made Covid vaccines as quickly as they did — if they hadn't, the death toll would be far worse. But in the event of another pandemic, even if the world is able to develop a vaccine for a new pathogen in 100 days, it will still take a long time to get the vaccine to most of the population.... With good therapeutics, the risk of severe illness and death could drop significantly, and countries could decide to loosen restrictions on schools and businesses, reducing the disruption to education and the economy. What's more, imagine how people's lives would change if we're able to take the next step by linking testing and treatment. Anyone with early symptoms that might indicate Covid (or any other viral disease) could walk into a pharmacy or clinic anywhere in the world, get tested and, if positive for the virus, walk out with antivirals to take at home....

In short, although therapeutics didn't rescue us from Covid, they hold a lot of promise for saving lives and preventing future outbreaks from crippling health systems. But to make the most of that promise, the world needs to invest in the research and systems we'll need to find treatments much faster. That's why my foundation has supported a therapeutics accelerator at Duke University, but broader initiatives will be necessary to make lasting change. This will require substantial investment to bring together academia, industry and the latest software tools. But if we succeed, the next time the world faces an outbreak, we'll save millions more lives.
Gates offers several specific recommendations — including "investing in large libraries of drug compounds that researchers can quickly scan to see whether existing therapies work against new pathogens." And... With advances in artificial intelligence and machine learning, it's now possible to use computers to identify weak spots on pathogens that we already know about, and we'll be able to do the same when new pathogens arise. These technologies are also speeding up the search for new compounds that will attack those weak spots. With adequate funding, various groups could take the most promising new compounds through Phase 1 studies even before there's an epidemic, or at least have several leads that can be turned into a product quickly once we know what the target looks like.

An anonymous reader quotes a report from the BBC: Researchers have rejuvenated a 53-year-old woman's skin cells so they are the equivalent of a 23-year-old's. [...] The scientists in Cambridge believe that they can do the same thing with other tissues in the body. The head of the team, Prof Wolf Reik, of the Babraham Institute in Cambridge, told BBC News that he hoped that the technique could eventually be used to keep people healthier for longer as they grow older. [...] Prof Reich stressed though that the work, which has been published in the journal eLife, was at a very early stage. He said that there were several scientific issues to overcome before it could move out of his lab and into the clinic. But he said that demonstrating for the first time that cell rejuvenation is possible was a critical step forward.

Prof Reik's team used [a method, called iPS, that involves adding chemicals to adult cells to turn them into stem cells] on 53-year-old skin cells. But they cut short the chemical bath from 50 days to around 12. Dr Dilgeet Gill was astonished to find that the cells had not turned into embryonic stem cells -- but had rejuvenated into skin cells that looked and behaved as if they came from a 23-year old. He said: "I remember the day I got the results back and I didn't quite believe that some of the cells were 30 years younger than they were supposed to be. It was a very exciting day!"

The technique cannot immediately be translated to the clinic because the iPS method increases the risk of cancers. But Prof Reik was confident that now it was known that it is possible to rejuvenate cells, his team could find an alternative, safer method. "The long-term aim is to extend the human health span, rather than the lifespan, so that people can get older in a healthier way," he said. Prof Reik says some of the first applications could be to develop medicines to rejuvenate skin in older people in parts of the body where they have been cut or burned -- as a way to speed up healing. The researchers have demonstrated that this is possible in principle by showing that their rejuvenated skin cells move more quickly in experiments simulating a wound. The next step is to see if the technology will work on other tissues such as muscle, liver and blood cells.

A new immunotherapy that targets cells infected with Epstein-Barr Virus (EBV) has halted the progression of multiple sclerosis (MS) in a small trial. Perhaps even more incredibly, in some patients, it is possible that symptoms of MS were actually reversed, though this was not fully identified in the most recent presentation of results (PDF). IFLScience reports: [S]ignificant evidence has linked infection of EBV and the eventual development of MS. [...] Attempting to "transform treatment of Multiple Sclerosis," Atara Biotherapeutics has developed an allogeneic T-cell therapy called ATA188. The concept is simple -- when cells are infected with EBV, they express small proteins called antigens on the cell surface, and the immunotherapy contains immune cells that target and destroy them.

In a trial of 24 patients who received the therapy, 20 saw improvements or stability in their symptoms and no fatal or serious adverse effects were reported. Early brain scans suggest that some damaged nerve cells may have been "repaired" by the therapy in a process called remyelination, which could mean a reversal of damage caused by MS in the nervous system, but this has not yet been confirmed. While the results are extremely promising, it is an early Phase 1 trial with a small sample size and no placebo or control group, so it is unclear whether the results are significant at this stage. However, it is unlikely that this repair would occur naturally, suggesting the therapy is having a beneficial effect on some level.

In a new study published in the journal Nature Biomedical Engineering, researchers from Harvard and MIT detail work they've done on a "living cellular therapeutic device" that promises to protect humans from the harmful side effects antibiotics can have on our guts. Engadget reports: Per Science Daily, they modified a strain of bacteria that is frequently used in cheese production to deliver an enzyme that can break down beta-lactam antibiotics. Many of the most commonly prescribed antibiotics in the US, including penicillin, fall under that family. Using gene editing, they further modified how their bacterium synthesizes the enzyme to prevent it from transferring that capability to other bacteria. The result is a treatment that reduces the harmful effects of antibiotics while still allowing those drugs to do their work.

In a study involving mice, the researchers found their bacteria "significantly" reduced the damage ampicillin did to the test subject's gut microbes and allowed those communities to recover fully after just three days. By contrast, in mice that only received the antibiotic, the researchers saw a much greater loss of microbial diversity. "We are now focusing on getting these living therapies to patients and are finalizing the design of an effective, short, and inexpensive clinical trial," said Andres Cubillos-Ruiz, the lead author of the study.

Amazon workers only make up a third of US warehouse employees, but in 2021, they suffered 49 percent of the injuries for the entire warehouse industry, according to a report by advocacy group Strategic Organizing Center (or SOC). The Verge reports: After analyzing data from the Occupational Safety and Health Administration (OSHA), the union coalition found that Amazon workers are twice as likely to be seriously injured than people who work in warehouses for other companies. The report considers "serious injuries" to be ones where workers either have to take time off to recover or have their workloads reduced, following OSHA's report classification (pdf) of "cases with days away from work" and "cases with job transfer or restriction." The data shows that, over time, the company has been shifting more toward putting people on light duty, rather than having them take time off. The report authors also note that Amazon workers take longer to recover from injuries than employees at other companies: around 62 days on average, versus 44 across the industry.

Amazon employees have said it's not the work itself that's particularly dangerous but rather the grueling pace the company's automated systems demand. Amazon actually had workers go slower in 2020 to help combat COVID-19, which accounts for the notably lower injury rates that year. But, as the report notes, the injuries increased by around 20 percent between 2020 and 2021 as the company resumed its usual pace -- though the injury rates for 2021 were still lower than they were in 2019. [...] Unfortunately, this study's results tell the same story we've been hearing for years. Even with its reduced injury rates in 2020, Amazon workers were still hurt twice as often as other warehouse workers, according to SOC. Further reading: Amazon Workers At 100 More Facilities Want To Unionize (Yahoo Finance)

Apple's plan to add a highly anticipated blood-pressure monitor to its smartwatch has hit some snags and the technology isn't expected to be ready until 2024 at the earliest, Bloomberg reported Tuesday, citing people with knowledge of the matter. From the report: The company has teams working on an updated sensor and software for the Apple Watch that would determine if a user has high blood pressure, but accuracy has been a challenge during testing, said the people, who asked not to be identified because the matter is private. The feature has been planned for at least four years, but it's probably two years away from hitting the market and may slip until 2025, they said. Apple's shares were up about 1% at 9:41 a.m. in New York. Blood-pressure features may become a key selling point for smartwatches in coming years, but the technology hasn't been easy to master. Though Apple rivals such as Samsung have launched watches with the capability, they require monthly calibration with a traditional monitor. Last year, Alphabet-owned Fitbit launched a public study to test wrist-based blood-pressure measurement.

Psilocybin, a drug found in magic mushrooms, appears to free up the brains of people with severe depression in a way that other antidepressants do not, a study has found. The BBC reports: The results, based on brain scans of 60 people, mean the drug could treat depression in a unique way, the researchers say. Patients with depression are warned not to take psilocybin on their own. A synthetic form of the drug is tested on people in trials under strict medical conditions, with psychological support from experts provided before, during and after it is taken.

With depression, the brain can get stuck in a rut and locked into a particular negative way of thinking, he said. But when given psilocybin, people's brains opened up and became "more flexible and fluid" up to three weeks later. This could be seen in increased connections between regions of the brain when patients were scanned. These patients were more likely to experience an improvement in mood months later. Similar changes were not seen in the brains of people treated with a standard antidepressant.

The results, published in Nature Medicine, are taken from two studies. In the first, everyone received psilocybin; and in the second -- a randomized controlled trial - some were given the drug while others were given a different antidepressant. All participants also received talking therapies with registered mental health professionals. Brain scans were taken before, and then one day or three weeks after taking the therapy.

"At first glance, U.S. Covid cases appear to have plateaued over the last two weeks," reports NBC News, "with a consistent average of around 30,000 per day..."

"But disease experts say incomplete data likely masks an upward trend." "I do think we are in the middle of a surge, the magnitude of which I can't tell you," Zeke Emanuel, vice provost of global initiatives at the University of Pennsylvania, said. The BA.2 omicron subvariant, which now accounts for about 72 percent of U.S. cases and is more contagious than the original omicron variant, is fueling that spread, Emanuel added. "It's much more transmissible. It's around. We just don't have a lot of case counts," he said.

Emanuel and other experts cite a lack of testing as the primary reason cases are underreported. At the height of the omicron wave in January, the U.S. was administering more than 2 million tests per day. That had dropped to an average of about 530,000 as of Monday, the most recent data from the Centers for Disease Control and Prevention. "The milder symptoms become, the less likely people are to test or show up in official case counts," said David Dowdy, an epidemiologist at the Johns Hopkins Bloomberg School of Public Health. More people also now have access to at-home rapid tests that are free or covered by insurance, and most of those test results don't get reported to state health departments or the CDC.

"Case counts and testing are progressively becoming shaky indicators because we're not catching everyone in the system," said Dr. Jonathan Quick, an adjunct professor at the Duke Global Health Institute.

Some local data, however, does reveal recent spikes. Average Covid cases have risen nearly 80 percent in Nebraska, 75 percent in Arizona, 58 percent in New York and 55 percent in Massachusetts over the last two weeks. Wastewater surveillance similarly suggests that infections are rising in Colorado, Ohio and Washington, among other states.
The Johns Hopkins epidemiologist emphasized that hospitalization figures are more important than case counts.

"If we're seeing an increase in cases, but not an increase in severe cases, I think it's a very valid question of does that matter?"

An anonymous reader quotes a report from the Guardian: It's a sunny day on a city street as a green bus pulls up by the kerb. Onboard, a handful of passengers sit stony-faced as you step up to present your pass. But you cannot see your body -- only a floating pair of blue hands. It might sound like a bizarre dream, but the scenario is part of a virtual reality (VR) system designed to help people with agoraphobia -- those for whom certain environments, situations and interactions can cause intense fear and distress. Scientists say the approach enables participants to build confidence and ease their fears, helping them to undertake tasks in real life that they had previously avoided. The study also found those with more severe psychological problems benefited the most. "It leads to a real step-change in people's lives," said Prof Daniel Freeman, the lead researcher in the work, from the psychiatry department at the University of Oxford.

The VR experience begins in a virtual therapist's office before moving to scenarios such as opening the front door or being in a doctor's surgery, each with varying levels of difficulty. Participants are asked to complete certain tasks, such as asking for a cup of coffee, and are encouraged to make eye contact or move closer to other characters. Freeman said while the scenarios feel real, the computer-generated scenes allow participants to feel able to try something new or approach the situation differently. "There's a little bit of the conscious bit [of the brain] going: 'OK, it's OK, I know it's not real and therefore I can persist, try something new and do something differently,'" he said. "That enables people to apply it in the real world. Basically, if you get over something in VR, you will get over in the real world."

Writing in the Lancet Psychiatry journal, Freeman and colleagues report how they randomly allocated 174 patients with difficulties going outside and psychosis to use the "gameChange" VR technology alongside their usual care. Another 172 patients were allocated to receive their usual care alone. [...] The results show that six weeks after the trial began, those allocated to the VR therapy had a small but significant reduction in avoiding real-life situations because of agoraphobia, as well as less distress, compared with those who had only received their usual care. However, by six months there was no difference between the two groups. But further analysis revealed that those who had severe agoraphobia benefited most, and for these people the effect was sustained at six months. Such patients were able to complete, on average, two more activities than before -- such as going shopping or getting on a bus.